MorphoSys scientists working in the company’s labs in Planegg
MorphoSys scientists working in the company’s labs in Planegg

Our History

Our Successful Journey

MorphoSys transformed from an R&D technology provider into a global biopharmaceutical company.


MorphoSys founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr. Andreas Plückthun


Invention of the HuCAL Concept, synthetic library consisting of human antibody sequences for the generation of highly specific, fully human antibodies. Inventor: Achim Knappik, Dr. Simon Moroney, Prof. Dr. Andreas Plückthun (and others)


Move to IZB Gründerzentrum with ~30 employees; first partnership with Pharmacia & Upjohn


MorphoSys is listed on the Frankfurt stock exchange; partnership with Bayer



Move to our own building in Martinsried, ~100 employees


Growth through partnerships: Novartis, Janssen, Schering-Plough, Pfizer, Merck

Since 2007

Own drug development, e.g. with Xencor, GSK and others


Move to new building in Planegg: state-of-the-art office and lab, unifying all teams under one roof


Tremfya® is the first drug based on MorphoSys’ antibody technology to receive regulatory approval. Developed and marketed by Janssen for the treatment of plaque psoriasis


MorphoSys is listed on NASDAQ; MorphoSys US Inc. is established; MorphoSys and I-Mab enter strategic development and commercialization agreement for MOR210/TJ210


Jean-Paul Kress appointed as MorphoSys CEO in September

January 2020

MorphoSys and Incyte enter into collaboration and licensing agreement to further develop and commercialize tafasitamab globally

July 2020

The U.S. Food and Drug Administration (FDA) grants accelerated approval for Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma

November 2020

MorphoSys and Cherry Biolabs entered into a licensing agreement for innovative, multispecific Hemibody technology; MorphoSys and Xencor enter into collaboration exploring further combinations with tafasitamab and Xencor’s CD20xCD3 bispecific plamotamab

July 2021

Acquisition of Constellation Pharmaceuticals, a U.S. biotech company that adds exciting, pioneering science and two new product candidates to our pipeline

August 2021

Conditional approvals for Minjuvi® (tafasitamab) in the European Union and Canada in combination with lenalidomide in patients with a certain type of lymphoma

December 2023

Comprehensive Phase 3 MANIFEST-2 results of pelabresib and ruxolitinib combination in first-line myelofibrosis presented at the American Society of Hematology (ASH) 2023 Annual Meeting and Exposition

February 2024

MorphoSys enters into Business Combination Agreement to be acquired by Novartis for € 2.7 billion equity value and into Purchase Agreement with Incyte for the sale of tafasitamab